Global Finance News
24 Feb 2026, 23:49
Bristol Myers Squibb (NYSE: BMY) reported positive top-line results from a registrational Phase 2 study evaluating Reblozyl (luspatercept) in adults with alpha (α)-thalassemia.
The ongoing ex-U.S. trial met primary endpoints in both non-transfusion-dependent (NTD) and transfusion-dependent (TD) cohorts. In NTD patients, Reblozyl demonstrated a statistically significant and clinically meaningful increase in hemoglobin levels. In TD patients, the treatment achieved a significant reduction in red blood cell transfusion burden. All key secondary endpoints were also met, and the safety profile was consistent with prior thalassemia studies.
The data will be presented at an upcoming medical congress and discussed with China’s Center for Drug Evaluation. Reblozyl is already approved in the U.S. for certain beta thalassemia and myelodysplastic syndromes indications.
Source: Business Wire, February 23, 2026.
The ongoing ex-U.S. trial met primary endpoints in both non-transfusion-dependent (NTD) and transfusion-dependent (TD) cohorts. In NTD patients, Reblozyl demonstrated a statistically significant and clinically meaningful increase in hemoglobin levels. In TD patients, the treatment achieved a significant reduction in red blood cell transfusion burden. All key secondary endpoints were also met, and the safety profile was consistent with prior thalassemia studies.
The data will be presented at an upcoming medical congress and discussed with China’s Center for Drug Evaluation. Reblozyl is already approved in the U.S. for certain beta thalassemia and myelodysplastic syndromes indications.
Source: Business Wire, February 23, 2026.